PET Scans Ontario
PET Registry
 

What is the PET Registry?

The Ontario PET Registry makes PET scans available to patients in certain cases where some evidence supports the benefit of PET scanning, but the evidence is too weak to support funding through the Ontario Health Insurance Program (OHIP).

The Registry collects additional data from participating patients to strengthen the evidence supporting the use of PET scans for eligible indications.

How do I enroll in the PET Registry?

Patients Physicians

Speak with your physician to determine if you are eligible for the PET Registry, and whether a PET scan is an appropriate diagnostic or treatment assessment tool for you.

Information on the reason for the PET scan, and the results, are used to strengthen the evidence supporting the use of PET scanning for the indication.

Using the PET Registry for the first time? You must register before you can refer a patient. Then you will have access to submit a PET scan request online for the PET Registry and the PET Access Program.

  • Review the list of  registry indications below to determine whether your patient fits the eligibility criteria.
  • Register to get information about the PET Registry or request a PET scan online.

Cancer indications

These indications are eligible for reimbursement through the Ontario PET Registry.

  • Anal canal cancer: for the initial staging of patients with T2-T4 squamous cell carcinoma of the anal canal with or without evidence of nodal involvement on conventional anatomical imaging.
  • Lymphoma staging:
    • PET for the staging of Hodgkin’s or non-Hodgkin’s lymphoma being treated with curative intent:
      1. for the staging of limited disease as per conventional imaging
        or
      2. when imaging is equivocal for differentiating between limited and advanced stage disease.
    • PET for apparent limited stage nodal follicular lymphoma or other indolent non-Hodgkin’s lymphomas where curative radiation therapy is being considered for treatment
  • Melanoma: for the staging of melanoma patients with localized “high risk” tumours with potentially resectable disease; or for the evaluation of patients with melanoma and isolated metastasis at the time of recurrence when metastectomy is being contemplated.
  • Paediatric Registry (patients must be <18 years of age):
    • For the following cancer types (ICCC)
      • Bone/Cartilage - Osteosarcoma, Ewings sarcoma
      • Connective/Other soft tissue - Rhabdomyosarcoma, Other
      • Kidney - Renal Tumour
      • Liver - Hepatic Tumour
      • Lymphoma/PTLD – Hodgkin’s Lymphoma, Non-Hodgkin’s Lymphoma
      • Primary Brain - Astrocytoma, Medulloblastoma, Ependymoma, Other
      • Reproductive - Germ Cell Tumour
      • Sympathetic Nervous System - Neuroblastoma MIBG negative
      • Other – LCH, Melanoma of the Skin, Thyroid
    • For the following indications
      • Initial Staging
      • Monitoring response during treatment/determine response-based therapy
      • Rule out progression prior to further therapy
      • Suspected recurrence/relapse
      • Rule out persistent disease
      • Select optimal biopsy site

Neurological Indications

  • Epilepsy: for patients with medically-intractable epilepsy being assessed for epilepsy surgery